Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
Jun. 30, 2021 |
Dec. 31, 2021 |
Dec. 31, 2019 |
|
| Collaboration and License Agreement | |||
| Amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied | $ 7,424,000 | ||
| GSK Collaboration And License Agreement | |||
| Collaboration and License Agreement | |||
| Milestone payments received | $ 4,200,000 | ||
| Amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied | $ 803,000 | ||
| GlaxoSmithKline Intellectual Property Development Ltd | |||
| Collaboration and License Agreement | |||
| Amount of development milestone achieved | $ 3,200,000 | ||
| X | ||||||||||
- Definition Represents cash received upon achievement of development milestones. No definition available.
|
| X | ||||||||||
- Definition Represents cash received upon achievement of various development milestones under license agreements. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|